Navigation Links
China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2010 on August 16, 2010
Date:7/2/2010

BEIJING, July 2 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it will report its unaudited financial results for the first fiscal quarter ("1Q FY2010") ended June 30, 2010 before the U.S. market opens on August 16, 2010. The Company's 2010 fiscal year ends on March 31, 2011.

The Company's senior management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on August 16, 2010 (8:00 p.m. Beijing/Hong Kong time on August 16, 2010).

    Conference Call
    The dial-in details for the live conference call are as follows:
    - U.S. Toll Free Number: 1-866-543-6407
    - International Dial-in Number: 1-617-213-8898
      Passcode: CMEDCALL

A live webcast of the conference call will be available on http://ir.chinameditech.com .

A replay of this webcast will be available for one month on this website.

A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. U.S
'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and KISSING, Germany , July 30, ... a single use and computer-assisted ("robotic") colonoscopy system, today ... a worldwide recognized medical device executive, as a new ... Shamir is a highly respected global visionary in the ... served as President and Chief Executive Officer at Given ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... , , SAN DIEGO , Jan. 15 ... entry of a settlement agreement which will resolve the consolidated securities ... Master File No: 3:09-cv-00921-LAB-WMC. The defendants have agreed to pay ... the company has agreed to issue to the plaintiffs, class a ...
... , , , , , , ... Jan. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China ... a,leading fully integrated pharmaceutical company developing and producing,over-the-counter drugs in ... the Company has relocated its headquarters to its new buildings,in ...
Cached Medicine Technology:Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 2Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 3Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 4China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 2China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 3
(Date:7/30/2014)... Aquarium Research Institute (MBARI) have observed a deep-sea octopus ... than any other known animal. Throughout this time, the ... predators. This amazing feat represents an evolutionary balancing act ... plenty of time to develop within their eggs, and ... or no food. , Every few months for the ...
(Date:7/30/2014)... -- For patients with asthma, just believing an odor ... for at least 24 hours, a new study indicates. ... what you think you smell," study author Cristina Jaen, ... said in a Monell news release. "Asthmatics ... expect that an odor is harmful, our bodies react ...
(Date:7/30/2014)... who were breastfed for three months or more ... chronic inflammation associated with cardiovascular and metabolic diseases, ... Washington University in St. Louis. , "This study ... for children,s health decades later," said Molly W. ... and a co-author of the study with Thomas ...
(Date:7/30/2014)... ‚ÄúToday, we have said ¡Basta! (enough) to the ... to our children and our families. The SWEET Act ... to put the health of people first and make ... President and CEO of the National Alliance for Hispanic ... (SWEET) Act by Congresswoman Rosa L. DeLauro. , The ...
(Date:7/30/2014)... With the recent May 21st opening of the ... Museum Workshop in the Meatpacking District has been encountering some ... Carole Barnes, "We have had to re-write the description of ... who sell us so tourists don't confuse the two 9/11 ... we do and what the new Museum does in terms ...
Breaking Medicine News(10 mins):Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 2Health News:Deep-sea octopus broods eggs for over 4 years -- longer than any known animal 3Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Birthweight and breastfeeding have implications for children's health decades later 2Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5
... the Division of Allergy and Immunology at Cincinnati ... extend funding of his long-standing investigation into "Regulation ... award from the National Institute of Allergy and ... of research accomplishment." Eosinophilic disorders occur ...
... HealthDay Reporter , THURSDAY, July 22 (HealthDay News) ... a result of taking statins don,t seem to benefit from ... The conventional wisdom has been that to reduce the ... LDL, or "bad," cholesterol and increase your HDL, or ...
... specific brain regions in female patients with irritable bowel syndrome ... abdomen, along with diarrhea, constipation or both. ... the study appears in the July issue of the journal ... IBS is associated with both decreases and increases in grey ...
... include certain must-have vitamins in their diets to stave off ... Alberta. , A study of 43 children and teens ... disease showed that they also tended to have low bone ... and minerals. That means they should be getting more of ...
... study into the causes of deaths of workers at ... rates from all causes and cancer in general when ... known by occupational health researchers as the "healthy worker ... such as leukemia or multiple myeloma were slightly above ...
... total joint replacement registry based on carefully designed and ... cost-effectiveness and research, according to a paper published in ... and Related Research , a journal of the Association ... Total Joint Replacement Registry the nation,s largest such registry ...
Cached Medicine News:Health News:Doctor at Cincinnati Children's receives prestigious NIH MERIT Award 2Health News:Some on Statins May Not Need Boost in 'Good' Cholesterol 2Health News:Some on Statins May Not Need Boost in 'Good' Cholesterol 3Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 2Health News:Study finds structural brain alterations in patients with irritable bowel syndrome 3Health News:Study describes health effects of occupational exposures in Paducah Gaseous Diffusion Plant workers 2Health News:Kaiser Permanente demonstrates success of large-scale total joint replacement registry 2
... High Productivity, improved safety and lower cost per ... solution to sample prep bottlenecks in the busy ... amazingly compact and quiet centrifuge spins standard 5 ... yet it produces quality serum or plasma equal ...
The StatSpin Express 3 provides faster turnaround time and greater productivity for your laboratory....
... Used for temporary internal ... to the bladder. Supplied sterile ... one-time use. CAUTION: Periodic evaluation ... Sof-Flex stents must not remain ...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: